The significant association between high Rac1 expression and hormone receptors including ER status and Her2neu status in our study has been previously investigated, suggesting that a Rac1 inhibitor may be a promising treatment in endocrine-resistant breast cancer (38, 39). Here, RAC1 is linked to breast carcinoma.